Advertisement
YOU ARE HERE: LAT HomeCollectionsApotex Inc
IN THE NEWS

Apotex Inc

FEATURED ARTICLES
BUSINESS
April 13, 2007
Allergan Inc. said a U.S. federal appeals court ruled in favor of the company in a patent infringement suit against Apotex Inc., a Canadian generic-drug maker. The ruling bars Apotex from obtaining Food and Drug Administration approval to market a generic version of Irvine-based Allergan's eye drug Acular.
ARTICLES BY DATE
BUSINESS
May 23, 2007 | From Bloomberg News
Allergan Inc., a maker of eye and beauty products, accused Canadian generic drug maker Apotex Inc. of infringing five U.S. patents for preparations used in the treatment of glaucoma. Allergan said in a federal lawsuit filed Monday in Delaware that Apotex told the company in April that it was seeking U.S. Food and Drug Administration approval to market generic versions of Allergan's Alphagan ophthalmic solution.
Advertisement
BUSINESS
January 4, 2006 | From Bloomberg News
Allergan Inc. said it won a ruling temporarily blocking Apotex Inc. from making or selling a generic version of a treatment for eye inflammation. The ruling, issued Dec. 29 by U.S. District Judge Martin Jenkins in San Francisco, temporarily prohibits Apotex from manufacturing or selling a generic version of Allergan's Acular in the U.S., Allergan spokeswoman Caroline Van Hove said. Irvine-based Allergan, which also makes the anti-wrinkle drug Botox, sued Apotex over patents for Acular in 2001.
BUSINESS
April 13, 2007
Allergan Inc. said a U.S. federal appeals court ruled in favor of the company in a patent infringement suit against Apotex Inc., a Canadian generic-drug maker. The ruling bars Apotex from obtaining Food and Drug Administration approval to market a generic version of Irvine-based Allergan's eye drug Acular.
BUSINESS
May 23, 2007 | From Bloomberg News
Allergan Inc., a maker of eye and beauty products, accused Canadian generic drug maker Apotex Inc. of infringing five U.S. patents for preparations used in the treatment of glaucoma. Allergan said in a federal lawsuit filed Monday in Delaware that Apotex told the company in April that it was seeking U.S. Food and Drug Administration approval to market generic versions of Allergan's Alphagan ophthalmic solution.
BUSINESS
January 1, 2004 | From Bloomberg News
A federal judge in San Francisco on Wednesday upheld Allergan Inc.'s patent for its top-selling eye drug Acular, blocking Apotex Inc. from selling a competing product. The ruling may help Allergan in a government antitrust investigation. U.S. District Judge Martin Jenkins said Apotex could not sell a generic version of Acular until Allergan's patent expired in 2009. Acular is used to treat allergy, photophobia, post-surgical pain and post-surgical inflammation.
BUSINESS
September 1, 2006 | From Bloomberg News
Bristol-Myers Squibb Co. and Sanofi-Aventis on Thursday won a bid to stop Apotex Inc. from selling its cheaper generic version of the Plavix heart pill, the world's second-biggest-selling medicine. Bristol-Myers shares surged. U.S. District Court Judge Sidney H. Stein in New York ruled that Bristol-Myers and Sanofi were likely to win their patent-infringement suit against Apotex and wouldn't be able to recoup losses if generic sales were allowed to continue.
BUSINESS
May 19, 2005 | From Bloomberg News
A U.S. appeals court Wednesday gave generic-drug maker Apotex Inc. a second chance to seek the invalidation of a patent for Acular, Allergan Inc.'s treatment for eye inflammations. The U.S. Court of Appeals for the Federal Circuit in Washington ruled that a San Francisco judge committed a "clear error" when he concluded that Allergan's patent was valid because it wasn't an obvious variation of earlier known compounds.
BUSINESS
May 30, 1991 | MICHAEL PARRISH and JANE APPLEGATE, TIMES STAFF WRITERS
More than a year ago, sister drug companies in the United States and Canada first laid plans to enter the health marketplace with a low-cost generic equivalent for the most widely used AIDS drug, AZT. Now, with the federal government adding weight to their efforts to break the monopoly held by AZT's manufacturer, Burroughs Wellcome Co., they may get the chance, slicing the cost of the life-extending drug as much as 75% in the process.
BUSINESS
August 15, 2006 | From the Associated Press
Bristol-Myers Squibb Co. and Sanofi-Aventis said Monday that they filed for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of blood thinner Plavix and force it to recall product already sold. The companies also said they had begun discounting Plavix to stem the loss of market share. A hearing on the motion is set for Friday in the U.S.
BUSINESS
December 9, 2006 | From the Associated Press
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
BUSINESS
September 1, 2006 | From Bloomberg News
Bristol-Myers Squibb Co. and Sanofi-Aventis on Thursday won a bid to stop Apotex Inc. from selling its cheaper generic version of the Plavix heart pill, the world's second-biggest-selling medicine. Bristol-Myers shares surged. U.S. District Court Judge Sidney H. Stein in New York ruled that Bristol-Myers and Sanofi were likely to win their patent-infringement suit against Apotex and wouldn't be able to recoup losses if generic sales were allowed to continue.
BUSINESS
August 15, 2006 | From the Associated Press
Bristol-Myers Squibb Co. and Sanofi-Aventis said Monday that they filed for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of blood thinner Plavix and force it to recall product already sold. The companies also said they had begun discounting Plavix to stem the loss of market share. A hearing on the motion is set for Friday in the U.S.
BUSINESS
January 4, 2006 | From Bloomberg News
Allergan Inc. said it won a ruling temporarily blocking Apotex Inc. from making or selling a generic version of a treatment for eye inflammation. The ruling, issued Dec. 29 by U.S. District Judge Martin Jenkins in San Francisco, temporarily prohibits Apotex from manufacturing or selling a generic version of Allergan's Acular in the U.S., Allergan spokeswoman Caroline Van Hove said. Irvine-based Allergan, which also makes the anti-wrinkle drug Botox, sued Apotex over patents for Acular in 2001.
BUSINESS
May 19, 2005 | From Bloomberg News
A U.S. appeals court Wednesday gave generic-drug maker Apotex Inc. a second chance to seek the invalidation of a patent for Acular, Allergan Inc.'s treatment for eye inflammations. The U.S. Court of Appeals for the Federal Circuit in Washington ruled that a San Francisco judge committed a "clear error" when he concluded that Allergan's patent was valid because it wasn't an obvious variation of earlier known compounds.
BUSINESS
January 1, 2004 | From Bloomberg News
A federal judge in San Francisco on Wednesday upheld Allergan Inc.'s patent for its top-selling eye drug Acular, blocking Apotex Inc. from selling a competing product. The ruling may help Allergan in a government antitrust investigation. U.S. District Judge Martin Jenkins said Apotex could not sell a generic version of Acular until Allergan's patent expired in 2009. Acular is used to treat allergy, photophobia, post-surgical pain and post-surgical inflammation.
BUSINESS
December 9, 2006 | From the Associated Press
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
BUSINESS
June 6, 2006 | From Reuters
Allergan Inc., maker of the Botox wrinkle treatment, said the Food and Drug Administration approved its Juvederm dermal filler treatment targeting the folds alongside the nose and mouth. Separately, Allergan said it won a court ruling that would block Apotex Inc. from selling a generic version of a treatment for eye inflammation until 2009.
BUSINESS
May 30, 1991 | MICHAEL PARRISH and JANE APPLEGATE, TIMES STAFF WRITERS
More than a year ago, sister drug companies in the United States and Canada first laid plans to enter the health marketplace with a low-cost generic equivalent for the most widely used AIDS drug, AZT. Now, with the federal government adding weight to their efforts to break the monopoly held by AZT's manufacturer, Burroughs Wellcome Co., they may get the chance, slicing the cost of the life-extending drug as much as 75% in the process.
Los Angeles Times Articles
|